Journal of affective disorders · 2026
Prenatal maternal anxiety and offspring development: Insights from neurobehavioral assessments and cord blood metabolomics.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Ming, Feng Zixuan, Wu Zixin, Zhang Xiuqi, Wen Yazhou, Zhang Min, Zhou Jin, Yue Wei, Feng Shanwu
Аннотация
BACKGROUND: Prenatal maternal anxiety has been shown to predict various detrimental consequences for the social, behavioral, and cognitive development of offspring. This study examined the associations between prenatal maternal anxiety and the development of offspring during the first year after birth.
METHODS: Prenatal anxiety was assessed in 148 patients via standardized clinical rating scales (the Perinatal Anxiety Screening Scale, PASS) at the specific time point of the day before delivery. Newborn neurodevelopment was quantified using the Neonatal Behavioral Neurological Assessment (NBNA) score, while infant development was longitudinally assessed with the Ages and Stages Questionnaire 3rd Edition (ASQ-3) and Social-Emotional 2nd Edition (ASQ:SE-2). Furthermore, we randomly selected 60 mothers and used newborn cord blood samples for untargeted metabolomics analysis. At 2 months, 6 months and 12 months after delivery, participants were followed up using a combination of online questionnaires and telephone interviews.
RESULTS: The results indicated that infants born to mothers with anxiety symptoms during pregnancy exhibited significant growth retardation over the first 30 days of life. Although there was essentially no significant difference in the screening results for the ASQ-3 and the ASQ:SE-2, the screening using the NBNA scale (P < 0.0001) revealed lower scores in the offspring of women with prenatal anxiety. The identified lipid metabolites were inversely related to the NBNA score [(l-carnitine: P < 0.0001) (3-hydroxy-3-methylglutaric acid: P < 0.0001) (mevalonate acid: P < 0.0001)].
CONCLUSION: An imbalance in the mevalonate-cholesterol pathway may be implicated in the neurodevelopmental impairments observed in children of prenatally anxious mothers.
METHODS: Prenatal anxiety was assessed in 148 patients via standardized clinical rating scales (the Perinatal Anxiety Screening Scale, PASS) at the specific time point of the day before delivery. Newborn neurodevelopment was quantified using the Neonatal Behavioral Neurological Assessment (NBNA) score, while infant development was longitudinally assessed with the Ages and Stages Questionnaire 3rd Edition (ASQ-3) and Social-Emotional 2nd Edition (ASQ:SE-2). Furthermore, we randomly selected 60 mothers and used newborn cord blood samples for untargeted metabolomics analysis. At 2 months, 6 months and 12 months after delivery, participants were followed up using a combination of online questionnaires and telephone interviews.
RESULTS: The results indicated that infants born to mothers with anxiety symptoms during pregnancy exhibited significant growth retardation over the first 30 days of life. Although there was essentially no significant difference in the screening results for the ASQ-3 and the ASQ:SE-2, the screening using the NBNA scale (P < 0.0001) revealed lower scores in the offspring of women with prenatal anxiety. The identified lipid metabolites were inversely related to the NBNA score [(l-carnitine: P < 0.0001) (3-hydroxy-3-methylglutaric acid: P < 0.0001) (mevalonate acid: P < 0.0001)].
CONCLUSION: An imbalance in the mevalonate-cholesterol pathway may be implicated in the neurodevelopmental impairments observed in children of prenatally anxious mothers.